论文部分内容阅读
礼莱公司正在研究一种应用选择性抗雌激素的治疗/预防骨质疏松症的新药。该公司指出,化合物雷洛昔芬(raloxi—fene,LY—139481)正准备进入第Ⅲ期临床试验。该化合物和雌激素一样,对骨质和脂质都有极好的作用,但是,和雌激素的不同之处是对子宫没有激化作用。雌激素对子宫的激化作用会增加子宫内膜癌的危险性。但如果同时服用一种孕激素,可避免致癌作用,使用激素联合治疗的妇女通常继续有月经,这一点可以说是和HRT不一致的主要原因。此外,虽然尚未证实用雌
Lilly is working on a new drug that treats / prevents osteoporosis with selective anti-estrogen. The company noted that the compound raloxi-fene (LY-139481) is preparing to enter Phase III clinical trials. The compound, like estrogen, has an excellent effect on the bones and lipids, but differs from estrogen in that there is no exacerbation of the uterus. Estrogen stimulation of the uterus will increase the risk of endometrial cancer. However, if you take a progestin at the same time, to avoid carcinogenic effects, hormone therapy combined with women often continue to have menstruation, which can be said to be inconsistent with the HRT main reason. In addition, although not confirmed with the female